more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.

Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

by Sanghamitra Saha Published on February 14,2019

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

by Zacks Equity Research Published on February 13,2019

The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion

pharmaceuticals

Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

by Mark Vickery Published on February 12,2019

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and U.S. Bancorp (USB).

Is Alexion (ALXN) a Great Growth Stock?

by Zacks Equity Research Published on February 11,2019

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Alexion (ALXN).

ALXNPositive Net Change

medical

Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

by Zacks Equity Research Published on February 04,2019

Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

biotechs

Economic & Earnings Data Deluge

by Zacks Equity Research Published on February 04,2019

Economic & Earnings Data Deluge

earnings

Q4 Earnings Soldier on Gamely: GOOGL, CLX & More

by Mark Vickery Published on February 04,2019

Eearnings reports to this point, based on strong consumer confidence and historically robust employment data (see Friday's 300K+ new jobs created last month), have been surprisingly positive amid these various and unpredictable headwinds.

earnings

Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on February 04,2019

Alexion beat both earnings and sales estimates in the fourth quarter of 2018.

ALXNPositive Net Change

biotechs

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on January 31,2019

Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.

biotechs

Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

by Zacks Equity Research Published on January 29,2019

Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

biotechs

4 Biotechs That Are Potential Buyouts Post Celgene Deal

by Ekta Bagri Published on January 08,2019

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure

by Zacks Equity Research Published on December 27,2018

Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.

biotechs

Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder

by Zacks Equity Research Published on December 24,2018

Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.

biotechs

Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija

by Zacks Equity Research Published on December 24,2018

Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.

biotechs

Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

by Zacks Equity Research Published on December 21,2018

Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.

biotechs

Allakos (ALLK) Catches Eye: Stock Jumps 6.5%

by Zacks Equity Research Published on December 21,2018

Allakos (ALLK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

medical

Alexion Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research Published on December 20,2018

Alexion Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ALXNPositive Net Change

medical

Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

by Zacks Equity Research Published on December 19,2018

Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.

biotechs

Achillion Reports Positive Interim Data on Factor D Inhibitors

by Zacks Equity Research Published on December 18,2018

Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.